Athira Pharma Stock Performance
| ATHA Stock | USD 0.33 0.02 6.06% |
The firm shows a Beta (market volatility) of 0.66, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Athira Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Athira Pharma is expected to be smaller as well. At this point, Athira Pharma has a negative expected return of -0.83%. Please make sure to confirm Athira Pharma's skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Athira Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Athira Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Disposition of 36667 shares by Worthington Mark of Athira Pharma subject to Rule 16b-3 | 12/31/2024 |
2 | Disposition of 8510 shares by Worthington Mark of Athira Pharma at 0.5619 subject to Rule 16b-3 | 01/02/2025 |
3 | Athira Pharma to Pay 4 Million Over Alleged Research Misconduct - Marketscreener.com | 01/06/2025 |
4 | Athira Pharma stock hits 52-week low at 0.41 amid steep decline - Investing.com | 02/25/2025 |
5 | Acquisition by Worthington Mark of 7767 shares of Athira Pharma at 2.41 subject to Rule 16b-3 | 02/26/2025 |
6 | Athira Pharma Inc Reports Annual EPS of -2.52, Narrowing Losses and Reducing Expenses in 2024 | 02/27/2025 |
7 | Acquisition by Worthington Mark of 57263 shares of Athira Pharma subject to Rule 16b-3 | 03/03/2025 |
8 | Disposition of 2525 shares by Worthington Mark of Athira Pharma at 0.566 subject to Rule 16b-3 | 03/04/2025 |
9 | Acquisition by Perceptive Advisors Llc of 163954 shares of Athira Pharma at 2.38 subject to Rule 16b-3 | 03/07/2025 |
10 | Disposition of 2525 shares by Kevin Church of Athira Pharma at 0.566 subject to Rule 16b-3 | 03/19/2025 |
| Begin Period Cash Flow | 91.2 M |
Athira |
Athira Pharma Relative Risk vs. Return Landscape
If you would invest 58.00 in Athira Pharma on December 20, 2024 and sell it today you would lose (25.12) from holding Athira Pharma or give up 43.31% of portfolio value over 90 days. Athira Pharma is currently does not generate positive expected returns and assumes 4.7182% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Athira, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Athira Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Athira Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Athira Pharma, and traders can use it to determine the average amount a Athira Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1762
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ATHA |
Estimated Market Risk
| 4.72 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.83 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Athira Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Athira Pharma by adding Athira Pharma to a well-diversified portfolio.
Athira Pharma Fundamentals Growth
Athira Stock prices reflect investors' perceptions of the future prospects and financial health of Athira Pharma, and Athira Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Athira Stock performance.
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.55 | ||||
| Current Valuation | (36.53 M) | ||||
| Shares Outstanding | 39.04 M | ||||
| Price To Book | 0.30 X | ||||
| EBITDA | (100.9 M) | ||||
| Net Income | (96.94 M) | ||||
| Cash And Equivalents | 252.4 M | ||||
| Cash Per Share | 6.67 X | ||||
| Total Debt | 1.22 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 26.40 X | ||||
| Book Value Per Share | 1.15 X | ||||
| Cash Flow From Operations | (97.17 M) | ||||
| Earnings Per Share | (2.52) X | ||||
| Market Capitalization | 13.52 M | ||||
| Total Asset | 58.78 M | ||||
| Retained Earnings | (406.15 M) | ||||
| Working Capital | 41.71 M | ||||
About Athira Pharma Performance
By analyzing Athira Pharma's fundamental ratios, stakeholders can gain valuable insights into Athira Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Athira Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Athira Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (491.44) | (516.02) | |
| Return On Tangible Assets | (1.65) | (1.57) | |
| Return On Capital Employed | (2.21) | (2.32) | |
| Return On Assets | (1.65) | (1.57) | |
| Return On Equity | (2.16) | (2.05) |
Things to note about Athira Pharma performance evaluation
Checking the ongoing alerts about Athira Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Athira Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Athira Pharma generated a negative expected return over the last 90 days | |
| Athira Pharma has some characteristics of a very speculative penny stock | |
| Athira Pharma has high historical volatility and very poor performance | |
| Athira Pharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (96.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Athira Pharma currently holds about 252.4 M in cash with (97.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Disposition of 2525 shares by Kevin Church of Athira Pharma at 0.566 subject to Rule 16b-3 |
- Analyzing Athira Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Athira Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Athira Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Athira Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Athira Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Athira Pharma's stock. These opinions can provide insight into Athira Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Athira Stock analysis
When running Athira Pharma's price analysis, check to measure Athira Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Athira Pharma is operating at the current time. Most of Athira Pharma's value examination focuses on studying past and present price action to predict the probability of Athira Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Athira Pharma's price. Additionally, you may evaluate how the addition of Athira Pharma to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |